At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
PP-001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis Having Chronic Inflammation
In Brief
A Phase 2 clinical trial evaluating PP-001 for Non-infectious Uveitis. Completed, enrolled 12 participants across 9 sites in 5 countries.
Detailed Summary
In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase) and has shown pre-clinical efficacy in treatment of non-infectious uveitis. PP-001 will be administered to participants as a single intravitreal injection in ascending doses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-infectious Uveitis
CountriesAustria, Belgium, Germany, Netherlands, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedAug 2018
Primary CompletionNov 2018
Study CompletionApr 2019
TodayJul 2026
First PostedAug 16, 2018
Enrollment StartJan 1, 2017
Primary CompletionNov 1, 2018
Study CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.9 years ago
Interventions
PP-001drug
Drug - no placebo